OKYO - OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024 | Benzinga
LONDON and NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ:OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, announces that it will be rescheduling a Key Opinion Leader (KOL) event entitled "KOL Event Presenting Comprehensive Detailed Results from the Phase 2 Trial of OK-101 in Dry Eye Disease" originally planned for April 9th, 2024 at 12:00 PM ET until May 2024. The Company is rescheduling its event so that it can incorporate additional key analyses of its clinical data which it plans to present at upcoming ophthalmic conferences.
OKYO is planning to make a presentation at "Dry Horizons Symposium Navigating the Future of Dry Eye Research", an event preceding the Association for Research in Vision and Ophthalmology (ARVO) conference with details provided below.
Date: Friday May 3, 2024, 2:50-3:45 PM PST
Venue: Four Seasons Seattle, WA
Presenter: Gary Jacob, PhD, Chief Executive Officer
About Dry Horizons Symposium
Uniting clinical leaders and industry innovators to tackle significant challenges in the dry eye market. With the rising prevalence of dry eye disease, the shortcomings of existing treatments, as well as new opportunities for advancing clinical pathways based on recent successful therapies, this symposium will provide in-depth coverage of the global landscape of Dry Eye ...